Compounds > 3,5-dichlorobenzonitrile
Page last updated: 2024-12-07

3,5-dichlorobenzonitrile

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

3,5-dichlorobenzonitrile: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID81052
CHEMBL ID51500
SCHEMBL ID633226
MeSH IDM0539328

Synonyms (29)

Synonym
nsc 109596
einecs 229-495-3
ai3-34463
unii-ey25ks4r7x
ey25ks4r7x ,
nsc-109596
nsc109596
6575-00-4
inchi=1/c7h3cl2n/c8-6-1-5(4-10)2-7(9)3-6/h1-3
3,5-dichlorobenzonitrile
benzonitrile, 3,5-dichloro-
3,5-dichlorobenzonitrile, 97%
AC-4362
D3261
CHEMBL51500
3,5-dichloro-benzonitrile
AKOS009158189
FT-0614559
CL8178
SCHEMBL633226
W-104788
mfcd00001800
DTXSID00215950
3,5-dichlorobenzonitril
AS-14514
SB38160
EN300-97050
CS-W017636
Z452434108
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (1)

Assay IDTitleYearJournalArticle
AID216482Ability to inhibit expression of Vascular cell adhesion molecule 1; No effect2001Bioorganic & medicinal chemistry letters, Jul-23, Volume: 11, Issue:14
Nitrobenzene compounds inhibit expression of VCAM-1.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (40.00)29.6817
2010's3 (60.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 20.47

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index20.47 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index4.63 (4.65)
Search Engine Demand Index15.26 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (20.47)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
1-chloro-2-nitrobenzene
[no description available]		210C-nitro compound;
monochlorobenzenes
difluorodinitrobenzene sulfone
[no description available]		210
bromoxynil
bromoxynil: RN given refers to parent cpd; structure. 3,5-dibromo-4-hydroxybenzonitrile : A dibromobenzene that is 2,6-dibromophenol substituted by a cyano group at position 4.		2.0410dibromobenzene;
hydroxynitrile;
phenols		environmental contaminant;
herbicide;
xenobiotic
ConditionIndicatedRelationship StrengthStudiesTrials
Autoimmune Disease
[description not available]		0210
Allergic Reaction
[description not available]		0210
Innate Inflammatory Response
[description not available]		0210
Autoimmune Diseases
Disorders that are characterized by the production of antibodies that react with host tissues or immune effector cells that are autoreactive to endogenous peptides.		0210
Hypersensitivity
Altered reactivity to an antigen, which can result in pathologic reactions upon subsequent exposure to that particular antigen.		0210
Inflammation
A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.		0210